肝移植受者戊型肝炎病毒感染

郭藩盛; 曾强; 窦剑

doi:10.3969/j.issn.1674-7445.2023216

肝移植受者戊型肝炎病毒感染

doi: 10.3969/j.issn.1674-7445.2023216

050051　石家庄，河北医科大学第三医院肝胆外科

基金项目: 2022年度河北省医学科学研究课题计划（20220121）

详细信息

作者简介:

通讯作者:
窦剑（ORCID 0000-0002-2750-8715），主任医师，研究方向为肝移植，Email：2423978344@qq.com

中图分类号: R639,R619+.3
计量
- 文章访问数: 23
- HTML全文浏览量: 9
- PDF下载量: 5
- 被引次数: 0
出版历程
- 收稿日期: 2023-10-23
- 录用日期: 2024-01-18
- 网络出版日期: 2024-02-29

Hepatitis E virus infection in liver transplant recipients

Department of Hepatobiliary Surgery, Hebei Medical University Third Hospital, Shijiazhuang 050051, China

More Information

Corresponding author: Dou Jian, Email: 2423978344@qq.com

摘要

摘要: 戊型肝炎病毒感染是急性病毒性肝炎的常见病因。近年来，戊型肝炎发病率呈上升趋势，逐渐成为世界范围内急性病毒性肝炎的重要病因。年龄、性别、免疫抑制强度、经济社会因素均是戊型肝炎病毒感染的危险因素。肝移植受者术后需长期应用免疫抑制药进行抗排斥反应治疗，处于免疫抑制状态，易感染戊型肝炎病毒且有引起肝纤维化及肝硬化的风险。因此，在临床工作中应重点关注肝移植受者，同时应进一步明确相关危险因素，以便辅助诊断和采取更严格的预防措施。本文根据现有文献对戊型肝炎病毒病原学特点以及肝移植受者戊型肝炎病毒感染的流行病学特征、临床表现、诊断及治疗进行综述，以期在临床上更好地对肝移植受者戊型肝炎病毒感染进行监测、治疗及预防，改善肝移植受者的预后。
- 戊型肝炎病毒 /
- 肝移植 /
- 流行病学特征 /
- 慢性戊型肝炎 /
- 肝纤维化 /
- 肝硬化 /
- 利巴韦林 /
- 持续病毒学应答
Abstract: Hepatitis E virus infection is a common cause of acute viral hepatitis. In recent years, the incidence of hepatitis E has shown an increasing trend, which has gradually become an important cause of acute viral hepatitis worldwide. Age, sex, intensity of immunosuppression and socio-economic factors are all risk factors for hepatitis E virus infection. Liver transplant recipients require long-term use of immunosuppressive drugs for anti rejection treatment, prone to hepatitis E virus infection and at the risk of liver fibrosis and cirrhosis due to immunosuppression status. Therefore, special attention should be paid to liver transplant recipients in clinical practice. Meantime, related risk factors should be identified to assist diagnosis and take stricter preventive measures. According to literature review, the etiological characteristics of hepatitis E virus and the epidemiological characteristics, clinical manifestations, diagnosis and treatment of hepatitis E virus infection in liver transplant recipients were reviewed, aiming to properly monitor, treat and prevent hepatitis E virus infection in liver transplant recipients in clinical practice, improving the prognosis of liver transplant recipients.
- Hepatitis E virus /
- Liver transplantation /
- Epidemiological characteristics /
- Chronic hepatitis E /
- Liver fibrosis /
- Cirrhosis /
- Ribavirin /
- Sustained virological response

HTML全文

参考文献(50)

[1]	中华医学会肝病学分会. 戊型肝炎防治共识[J]. 中华肝脏病杂志, 2022, 30(8): 820-831. DOI: 10.3760/cma.j.cn501113-20220729-00401. Chinese Society of Hepatology. Consensus on prevention and treatment of hepatitis E[J]. Chin J Hepatol, 2022, 30(8): 820-831. DOI: 10.3760/cma.j.cn501113-20220729-00401.
[2]	CARTER M, SOLSRUD K, YEDDULA S, et al. Hepatitis E diagnosis and management after liver, kidney, or heart transplant: a single-center experience[J]. Transplant Proc, 2022, 54(7): 1737-1741. DOI: 10.1016/j.transproceed.2022.04.025.
[3]	TAKAKUSAGI S, KAKIZAKI S, TAKAGI H. The diagnosis, pathophysiology, and treatment of chronic hepatitis E virus infection-a condition affecting immunocompromised patients[J]. Microorganisms, 2023, 11(5): 1303. DOI: 10.3390/microorganisms 11051303.
[4]	ZHOU Y, ZHAO C, TIAN Y, et al. Characteristics and functions of HEV proteins[J]. Adv Exp Med Biol, 2023, 1417: 15-32. DOI: 10.1007/978-981-99-1304-6_2.
[5]	LIU X, WANG M, YIN X. Cellular organelles involved in hepatitis E virus infection[J]. Pathogens, 2021, 10(9): 1206. DOI: 10.3390/pathogens10091206.
[6]	WANG B, MAHSOUB HM, LI W, et al. Ribavirin treatment failure-associated mutation, Y1320H, in the RNA-dependent RNA polymerase of genotype 3 hepatitis E virus (HEV) enhances virus replication in a rabbit HEV infection model[J]. mBio, 2023, 14(2): e0337222. DOI: 10.1128/mbio.03372-22.
[7]	DING Q, HELLER B, CAPUCCINO JM, et al. Hepatitis E virus ORF3 is a functional ion channel required for release of infectious particles[J]. Proc Natl Acad Sci U S A, 2017, 114(5): 1147-1152. DOI: 10.1073/pnas.1614955114.
[8]	PEZZONI G, STERCOLI L, PEGOIANI E, et al. Antigenic characterization of ORF2 and ORF3 proteins of hepatitis E Virus (HEV)[J]. Viruses, 2021, 13(7): 1385. DOI: 10.3390/v13071385.
[9]	李云龙, 黄芬. 戊型肝炎病毒跨种间传播研究进展[J]. 临床肝胆病杂志, 2023, 39(11): 2538-2542. LI YL, HUANG F. Research advances in the interspecies transmission of hepatitis E virus[J]. J Clin Hepatol, 2023, 39(11): 2538-2542.
[10]	高文光. 人畜共患性戊型肝炎病毒[J]. 中国畜牧业, 2023(16): 85-86. GAO WG. Zoonotic hepatitis E virus[J]. China Anim Ind, 2023(16): 85-86.
[11]	徐孟, 吴珂, 伍智勇等. 戊型肝炎病毒基因分型研究进展[J]. 中国病毒病杂志, 2022, 12(2): 138-143. DOI: 10.16505/j.2095-0136.2022.0020. XU M, WU K, WU ZY, et al. Research progress in genotyping of hepatitis E virus[J]. Chin J Viral Dis, 2022, 12(2): 138-143. DOI: 10.16505/j.2095-0136.2022.0020.
[12]	SRIDHAR S, YIP CC, WU S, et al. Transmission of rat hepatitis E virus infection to humans in Hong Kong: a clinical and epidemiological analysis[J]. Hepatology, 2021, 73(1): 10-22. DOI: 10.1002/hep.31138.
[13]	SRIDHAR S, YIP CCY, LO KHY, et al. Hepatitis E virus species C infection in humans, Hong Kong[J]. Clin Infect Dis, 2022, 75(2): 288-296. DOI: 10.1093/cid/ciab919.
[14]	VELAVAN TP, PALLERLA SR, JOHNE R, et al. Hepatitis E: an update on one health and clinical medicine[J]. Liver Int, 2021, 41(7): 1462-1473. DOI: 10.1111/liv.14912.
[15]	AHMAD T, NASIR S, MUSA TH, et al. Epidemiology, diagnosis, vaccines, and bibliometric analysis of the 100 top-cited studies on Hepatitis E virus[J]. Hum Vaccin Immunother, 2021, 17(3): 857-871. DOI: 10.1080/21645515.2020.1795458.
[16]	FERNÁNDEZ VILLALOBOS NV, KESSEL B, TORRES PÁEZ JC, et al. Seroprevalence of Hepatitis E virus in children and adolescents living in urban Bogotá: an explorative cross-sectional study[J]. Front Public Health, 2023, 11: 981172. DOI: 10.3389/fpubh.2023.981172.
[17]	NELSON KE, LABRIQUE AB, KMUSH BL. Epidemiology of genotype 1 and 2 hepatitis E virus infections[J]. Cold Spring Harb Perspect Med, 2019, 9(6): a031732. DOI: 10.1101/cshperspect.a031732.
[18]	LU J, LI Q, JIANG J, et al. Laboratory-based surveillance and clinical profile of sporadic HEV infection in Shanghai, China[J]. Virol Sin, 2021, 36(4): 644-654. DOI: 10.1007/s12250-020-00336-w.
[19]	疾病预防控制局. 2019年全国法定传染病疫情概况[EB/OL]. [2023-12-01]. http://www.nhc.gov.cn/jkj/s6873/202004/b1519e1bc1a944fc8ec176db600f68d1.shtml .
[20]	REN X, WU P, WANG L, et al. Changing epidemiology of hepatitis A and hepatitis e viruses in China, 1990-2014[J]. Emerg Infect Dis, 2017, 23(2): 276-279. DOI: 10.3201/2302.161095.
[21]	MARKAKIS GE, PAPATHEODORIDIS GV, CHOLONGITAS E. Epidemiology and treatment of hepatitis E in the liver transplantation setting: a literature review[J]. J Viral Hepat, 2022, 29(9): 698-718. DOI: 10.1111/jvh.13709.
[22]	KOMOLMIT P, ORANRAP V, SUKSAWATAMNUAY S, et al. Clinical significance of post-liver transplant hepatitis E seropositivity in high prevalence area of hepatitis E genotype 3: a prospective study[J]. Sci Rep, 2020, 10(1): 7352. DOI: 10.1038/s41598-020-64551-x.
[23]	DARSTEIN F, HÄUSER F, STRAUB BK, et al. Hepatitis E virus genotype 3 is a common finding in liver-transplanted patients undergoing liver biopsy for elevated liver enzymes with a low De Ritis ratio and suspected acute rejection: a real-world cohort[J]. Clin Transplant, 2018, 32(11): e13411. DOI: 10.1111/ctr.13411.
[24]	CARMO J, MARQUES S, MATEUS É, et al. Ribavirin for chronic hepatitis E in liver-transplant setting: a safe and highly effective therapy[J]. J Clin Gastroenterol, 2016, 50(7): 608. DOI: 10.1097/MCG.0000000000000554.
[25]	刘淼. 戊型肝炎病毒与血液安全的研究进展[J]. 中国输血杂志, 2023, 36(4): 359-364. DOI: 10.13303/j.cjbt.issn.1004-549x.2023.04.017. LIU M. Research progress on hepatitis E virus and blood safety[J]. Chin J Blood Transfus, 2023, 36(4): 359-364. DOI: 10.13303/j.cjbt.issn.1004-549x.2023.04.017.
[26]	FRANKAL M, SKOGLUND C, CASTEDAL M, et al. Hepatitis E virus infection, a risk for liver transplant recipients in Sweden[J]. Transplant Direct, 2022, 8(12): e1409. DOI: 10.1097/TXD.0000000000001409.
[27]	SRIDHAR S, CHENG VCC, WONG SC, et al. Donor-derived genotype 4 hepatitis E virus infection, Hong Kong, China, 2018[J]. Emerg Infect Dis, 2019, 25(3): 425-433. DOI: 10.3201/eid2503.181563.
[28]	SCHLOSSER B, STEIN A, NEUHAUS R, et al. Liver transplant from a donor with occult HEV infection induced chronic hepatitis and cirrhosis in the recipient[J]. J Hepatol, 2012, 56(2): 500-502. DOI: 10.1016/j.jhep.2011.06.021.
[29]	REEKIE I, IRISH D, IJAZ S, et al. Hepatitis E infection in stem cell and solid organ transplantpatients: a cross-sectional study: the importance of HEV RNA screening in peri-transplant period[J]. J Clin Virol, 2018, 107: 1-5. DOI: 10.1016/j.jcv.2018.07.011.
[30]	ÖĞÜT S, SAYINER AA, OTLU B, et al. Hepatitis E infection in solid organ transplant recipients in Turkey[J]. Turk J Gastroenterol, 2022, 33(1): 68-73. DOI: 10.5152/tjg.2021.21071.
[31]	MRZLJAK A, DINJAR-KUJUNDZIC P, VILIBIC-CAVLEK T, et al. Hepatitis E seroprevalence and associated risk factors in Croatian liver transplant recipients[J]. Rev Soc Bras Med Trop, 2019, 52: e20190302. DOI: 10.1590/0037-8682-0302-2019.
[32]	ANKCORN MJ, IJAZ S, POH J, et al. Toward systematic screening for persistent hepatitis E virus infections in transplant patients[J]. Transplantation, 2018, 102(7): 1139-1147. DOI: 10.1097/TP.000000000 0002097.
[33]	DONG R, CHANG D, LUO Z, et al. The burden of HEV-related acute liver failure in Bangladesh, China and India: a systematic review and meta-analysis[J]. BMC Public Health, 2023, 23(1): 2369. DOI: 10.1186/s12889-023-17302-2.
[34]	FANG L, ZHANG J, CHEN H, et al. Epidemiological characteristics and clinical manifestations of hepatitis E in a tertiary hospital in China: a retrospective study[J]. Front Microbiol, 2022, 12: 831968. DOI: 10.3389/fmicb.2021.831968.
[35]	Centers for Disease Control and Prevention (CDC). Hepatitis E among U. S. travelers, 1989-1992[J]. MMWR Morb Mortal Wkly Rep, 1993, 42(1): 1-4.
[36]	WU J, XIANG Z, ZHU C, et al. Extrahepatic manifestations related to hepatitis E virus infection and their triggering mechanisms[J]. J Infect, 2021, 83(3): 298-305. DOI: 10.1016/j.jinf.2021.07.021.
[37]	ZHANG H, RAO H, WANG Y, et al. Evaluation of an antigen assay for diagnosing acute and chronic hepatitis E genotype 4 infection[J]. J Gastroenterol Hepatol, 2019, 34(2): 458-465. DOI: 10.1111/jgh.14405.
[38]	KHUROO MS, KHUROO MS, KHUROO NS. Hepatitis E: discovery, global impact, control and cure[J]. World J Gastroenterol, 2016, 22(31): 7030-7045. DOI: 10.3748/wjg.v22.i31.7030.
[39]	PISCHKE S, SUNEETHA PV, BAECHLEIN C, et al. Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients[J]. Liver Transpl, 2010, 16(1): 74-82. DOI: 10.1002/lt.21958.
[40]	SOOTHILL G, HESSEY S, EROTOCRITOU M, et al. Diagnostic utility of hepatitis E virus antigen-specific ELISA versus PCR testing in a cohort of post liver transplant patients in a large university hospital[J]. J Clin Virol, 2018, 106: 44-48. DOI: 10.1016/j.jcv.2018.07.007.
[41]	KAMAR N, SELVES J, MANSUY JM, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients[J]. N Engl J Med, 2008, 358(8): 811-817. DOI: 10.1056/NEJMoa0706992.
[42]	HILLEBRANDT KH, ARSENIC R, HOFMANN J, et al. Acute graft dysfunction 17 years after liver transplant: a challenging clinical and histologic manifestation of hepatitis E[J]. Exp Clin Transplant, 2018, 16(3): 348-351. DOI: 10.6002/ect.2015.0343.
[43]	European Association for the Study of the Liver. EASL clinical practice guidelines on hepatitis E virus infection[J]. J Hepatol, 2018, 68(6): 1256-1271. DOI: 10.1016/j.jhep.2018.03.005.
[44]	KAMAR N, ABRAVANEL F, BEHRENDT P, et al. Ribavirin for hepatitis E virus infection after organ transplantation: a large European retrospective multicenter study[J]. Clin Infect Dis, 2020, 71(5): 1204-1211. DOI: 10.1093/cid/ciz953.
[45]	HUI W, WEI L. Treatment of hepatitis E[J]. Adv Exp Med Biol, 2023, 1417: 215-226. DOI: 10.1007/978-981-99-1304-6_15.
[46]	KAMAR N, ABRAVANEL F, GARROUSTE C, et al. Three-month pegylated interferon-alpha-2a therapy for chronic hepatitis E virus infection in a haemodialysis patient[J]. Nephrol Dial Transplant, 2010, 25(8): 2792-2795. DOI: 10.1093/ndt/gfq282.
[47]	CORNBERG M, PISCHKE S, MÜLLER T, et al. Sofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis E - the HepNet SofE pilot study[J]. J Hepatol, 2020, 73(3): 696-699. DOI: 10.1016/j.jhep.2020.05.020.
[48]	TSAREV SA, TSAREVA TS, EMERSON SU, et al. Successful passive and active immunization of cynomolgus monkeys against hepatitis E[J]. Proc Natl Acad Sci U S A, 1994, 91(21): 10198-10202. DOI: 10.1073/pnas.91.21.10198.
[49]	ZHU FC, ZHANG J, ZHANG XF, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial[J]. Lancet, 2010, 376(9744): 895-902. DOI: 10.1016/S0140-6736(10)61030-6.
[50]	YU XY, CHEN ZP, WANG SY, et al. Safety and immunogenicity of hepatitis E vaccine in elderly people older than 65 years[J]. Vaccine, 2019, 37(32): 4581-4586. DOI: 10.1016/j.vaccine.2019.04.006.